Cardiff Oncology, Inc.
A clinical-stage biotech company developing experimental cancer drugs, headquartered in San Diego. Its lead candidate, onvansertib, is an oral pill being tested against RAS-mutated metastatic colorectal cancer and other hard-to-treat tumors. The company began life in 2002 as a Florida shell company called Used Kar Parts, then rebranded as Xenomics, Trovagene, and finally Cardiff Oncology in 2020, when it set its sights on "turning the tide on cancer."
Bought 400.0K
Bought 1.38M
Bought 1.47M
Bought 272.7K
Granted 925.4K · Bought 4.8K
Bought 262.8K
Granted 28.9K · Bought 84.9K
Granted 75.6K · Bought 21.3K
Bought 67.7K
Granted 22.6K · Bought 65.1K
Granted 25.2K · Bought 170.0K · Sold 8.3K
Bought 24.7K
Granted 210.8K · Bought 23.0K
Granted 23.2K
Granted 26.0K · Bought 19.9K
Bought 20.0K
Bought 20.0K
Granted 25.5K · Bought 14.0K · Sold 19.2K
Bought 27.5K
Granted 29.3K · Bought 20.0K
Granted 35.4K · Bought 960 · Sold 35.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hunter Robert Merrill10% owner · 1 transaction | — | 5.07Mas of Apr 2012 | — | 400.0K | — |
| Pace Gary WDirector · 18 transactions | — | 4.03M | — | 1.38M | — |
| Mignone Roberto +1 co-filerFormer 10% Owner, 10% owner · 7 transactions | — | 2.97Mas of Nov 2016 | — | 1.47M | — |
| Sheinerman KiraDirector · 1 transaction | — | 909.1Kas of Aug 2008 | — | 272.7K | — |
| Welch William JChief Executive Officer, Director · 7 transactions | — | 842.6Kas of Jan 2018 | 925.4K | 4.8K | — |
| Cerrone GabrielDirector · 5 transactions | — | 725.8Kas of Dec 2012 | — | 262.8K | — |
| White LaleDirector · 3 transactions | — | 113.8Kas of Sep 2022 | 28.9K | 84.9K | — |
| Zaniboni SteveFormer CFO · 4 transactions | — | 97.0Kas of Apr 2016 | 75.6K | 21.3K | — |
| Levine James E.Chief Financial Officer · 9 transactions | — | 67.7Kas of Dec 2024 | — | 67.7K | — |
| Markin Rodney SDirector · 5 transactions | — | 31.1Kas of Mar 2021 | 22.6K | 65.1K | — |
| Tennant StanleyDirector · 9 transactions | — | 28.8Kas of Jun 2018 | 25.2K | 170.0K | 8.3K |
| Mohindru ManiChief Executive Officer, Director · 1 transaction | — | 24.7K | — | 24.7K | — |
| Erlander MarkChief Executive Officer, Director · 30 transactions | — | 24.5Kas of Nov 2022 | 210.8K | 23.0K | — |
| Billings PaulDirector · 2 transactions | — | 23.2Kas of Jan 2018 | 23.2K | — | — |
| Jacob Gary SDirector · 5 transactions | — | 21.5Kas of Mar 2021 | 26.0K | 19.9K | — |
| Schuh AntoniusCEO, Director · 1 transaction | — | 20.0Kas of Aug 2015 | — | 20.0K | — |
| Tannenbaum Renee PDirector · 3 transactions | — | 20.0Kas of Dec 2024 | — | 20.0K | — |
| Adams Thomas PHDDirector · 5 transactions | — | 18.9Kas of May 2020 | 25.5K | 14.0K | 19.2K |
| Armitage James ODirector · 3 transactions | — | 13.0Kas of Sep 2022 | — | 27.5K | — |
| Brancaccio John PDirector · 5 transactions | — | 12.3Kas of Mar 2021 | 29.3K | 20.0K | — |
| Kelemen VickiExec. VP and COO · 5 transactions | — | 6.1Kas of Mar 2021 | 35.4K | 960 | 35.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +4.31M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.